TWI796250B - 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式 - Google Patents

經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式 Download PDF

Info

Publication number
TWI796250B
TWI796250B TW111124239A TW111124239A TWI796250B TW I796250 B TWI796250 B TW I796250B TW 111124239 A TW111124239 A TW 111124239A TW 111124239 A TW111124239 A TW 111124239A TW I796250 B TWI796250 B TW I796250B
Authority
TW
Taiwan
Prior art keywords
compound
water
solvent
ray powder
powder diffraction
Prior art date
Application number
TW111124239A
Other languages
English (en)
Chinese (zh)
Other versions
TW202241854A (zh
Inventor
克雷格 貝茨
大衛 瑞德
Original Assignee
美商亞闊股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商亞闊股份有限公司 filed Critical 美商亞闊股份有限公司
Publication of TW202241854A publication Critical patent/TW202241854A/zh
Application granted granted Critical
Publication of TWI796250B publication Critical patent/TWI796250B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111124239A 2015-12-17 2016-12-16 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式 TWI796250B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268747P 2015-12-17 2015-12-17
US62/268,747 2015-12-17

Publications (2)

Publication Number Publication Date
TW202241854A TW202241854A (zh) 2022-11-01
TWI796250B true TWI796250B (zh) 2023-03-11

Family

ID=59057612

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111124239A TWI796250B (zh) 2015-12-17 2016-12-16 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
TW105141873A TWI771280B (zh) 2015-12-17 2016-12-16 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105141873A TWI771280B (zh) 2015-12-17 2016-12-16 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式

Country Status (19)

Country Link
US (3) US9981921B2 (cg-RX-API-DMAC7.html)
EP (2) EP3390369B1 (cg-RX-API-DMAC7.html)
JP (2) JP2018537499A (cg-RX-API-DMAC7.html)
KR (1) KR20180086508A (cg-RX-API-DMAC7.html)
CN (1) CN108368061A (cg-RX-API-DMAC7.html)
AU (2) AU2016369523B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018012095A2 (cg-RX-API-DMAC7.html)
CA (1) CA3006081A1 (cg-RX-API-DMAC7.html)
EA (2) EA202091691A1 (cg-RX-API-DMAC7.html)
ES (1) ES2935818T3 (cg-RX-API-DMAC7.html)
HK (1) HK1256825A1 (cg-RX-API-DMAC7.html)
IL (1) IL259556B2 (cg-RX-API-DMAC7.html)
MX (2) MX385671B (cg-RX-API-DMAC7.html)
NZ (1) NZ742695A (cg-RX-API-DMAC7.html)
PH (2) PH12018501246A1 (cg-RX-API-DMAC7.html)
SA (1) SA518391805B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201804670PA (cg-RX-API-DMAC7.html)
TW (2) TWI796250B (cg-RX-API-DMAC7.html)
WO (1) WO2017106642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106642A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2020012771A (es) 2015-12-17 2022-10-04 Arqule Inc Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
JP7641247B2 (ja) 2022-03-02 2025-03-06 日立建機株式会社 機械の性能診断装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010078421A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
EP1790634A3 (en) * 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal form and processes for preparing it
CA2710051C (en) * 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
US9802954B2 (en) * 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2017106642A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2020012771A (es) * 2015-12-17 2022-10-04 Arqule Inc Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
US9847831B2 (en) 2016-04-08 2017-12-19 Ciena Corporation Dual wavelenth optical time domain reflectometer systems and methods embedded in a WDM system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010078421A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Also Published As

Publication number Publication date
AU2022201947A1 (en) 2022-04-14
US20200002293A1 (en) 2020-01-02
MX2018007414A (es) 2018-11-09
MX385671B (es) 2025-03-18
SG11201804670PA (en) 2018-07-30
CA3006081A1 (en) 2017-06-22
MX2021000432A (es) 2022-07-28
IL259556B2 (en) 2023-09-01
EP3390369A4 (en) 2019-08-14
TW202241854A (zh) 2022-11-01
BR112018012095A2 (pt) 2018-11-27
AU2016369523A1 (en) 2018-06-07
EA036295B1 (ru) 2020-10-22
EP4019499A1 (en) 2022-06-29
JP2022031797A (ja) 2022-02-22
IL259556A (en) 2018-07-31
EA201891430A1 (ru) 2018-11-30
NZ742695A (en) 2022-10-28
US10717710B2 (en) 2020-07-21
US9981921B2 (en) 2018-05-29
PH12020551465A1 (en) 2021-07-26
US10227311B2 (en) 2019-03-12
AU2022201947B2 (en) 2023-07-27
SA518391805B1 (ar) 2022-12-21
US20170174636A1 (en) 2017-06-22
PH12018501246A1 (en) 2019-02-04
MX394320B (es) 2025-03-24
JP2018537499A (ja) 2018-12-20
TWI771280B (zh) 2022-07-21
TW201736352A (zh) 2017-10-16
EP3390369B1 (en) 2022-11-02
EP3390369A1 (en) 2018-10-24
WO2017106642A1 (en) 2017-06-22
HK1256825A1 (zh) 2019-10-04
EA202091691A1 (ru) 2021-01-29
IL259556B1 (en) 2023-05-01
AU2016369523B2 (en) 2021-12-23
US20180258055A1 (en) 2018-09-13
KR20180086508A (ko) 2018-07-31
CN108368061A (zh) 2018-08-03
ES2935818T3 (es) 2023-03-10

Similar Documents

Publication Publication Date Title
AU2013201519B2 (en) Salts of an epidermal growth factor receptor kinase inhibitor
AU2022201947B2 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
JP7496440B2 (ja) Trka阻害剤
TWI820182B (zh) 四氫哌喃基胺基-吡咯并嘧啶酮化合物的固體形式
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
HK40079038A (en) Method of preparing solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
EA044678B1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ СОЕДИНЕНИЯ ДИГИДРОХЛОРИДА (R)-6-(2-ФТОРФЕНИЛ)-N-(3-(2-(2-МЕТОКСИЭТИЛАМИНО)ЭТИЛ)ФЕНИЛ)-5,6-ДИГИДРОБЕНЗО[h]ХИНАЗОЛИН-2-АМИНА
HK1234747A1 (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
HK1234747B (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees